Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Sort descending Project Status Date Submission Received Date Recommendation Issued
Forteo Teriparatide (rDNA origin) injection Osteoporosis Withdrawn
Altace HCT Ramipril/hydrochlorothiazide Hypertension Cancelled
Zytram XL Tramadol hydrochloride Pain, acute Withdrawn
Onglyza Saxagliptin Diabetes mellitus, type 2 Withdrawn
Hemangiol Propranolol Infantile hemangioma Withdrawn
Sivextro Tedizolid phosphate Acute bacterial skin and skin structure infections Withdrawn
Aloxi (capsule) Palonosetron Chemotherapy-induced nausea and vomiting Withdrawn
VesiFlow Solifenacin succinate / tamsulosin hydrochloride Benign prostatic hyperplasia Withdrawn
Xyrem Sodium oxybate Narcolepsy Withdrawn
VFEND Voriconazole Aspergillosis, Invasive Withdrawn